From: Variability in total serum IgE over 1 year in severe asthmatics
Baseline characteristics (N = 41) | Low IgE group (< 76 IU/mL) (N = 10) | Intermediate IgE group (76–700 IU/mL) (N = 20) | High IgE group (> 700 IU/mL) (N = 11) | p value** | Difference specification*** |
---|---|---|---|---|---|
Age (years) | |||||
Mean (± SD) | 57.7 ± 15.7 | 49.5 ± 14.7 | 40.4 ± 13.4 | 0.03* | 1 vs 3 |
Gender | |||||
Male | 5 (29%) | 8 (47%) | 4 (24%) | 0.84 | |
Female | 5 (21%) | 12 (50%) | 7 (29%) | ||
Race | |||||
Caucasian | 10 (28%) | 19 (53%) | 7 (19%) | 0.03* | 1 vs 3; 2 vs 3 |
Other | 0 (0%) | 1 (20%) | 4 (80%) | ||
Smoking status | |||||
Never smoked | 6 (26%) | 12 (52%) | 5 (22%) | 0.27 | |
Former smoker | 3 (25%) | 7 (58%) | 2 (17%) | ||
Current smoker | 1 (17%) | 1 (17%) | 4 (66%) | ||
BMI (kg/m2) | |||||
< 30 | 9 (25%) | 17 (47%) | 10 (28%) | 0.79 | |
≥ 30 | 1 (25%) | 3 (75%) | 0 (0%) | ||
Medical history | |||||
Allergic rhinitis | 2 (9%) | 13 (56%) | 8 (35%) | 0.02* | 1 vs 3; 1 vs 2 |
Atopic dermatitis | 3 (17%) | 11 (61%) | 4 (22%) | 0.33 | |
GERD | 4 (44%) | 4 (44%) | 1 (11%) | 0.23 | |
Nasal polyps | 2 (25%) | 3 (38%) | 3 (38%) | 0.59 | |
Residence | |||||
City | 4 (18%) | 10 (45%) | 8 (36%) | 0.51 | |
Suburbs | 4 (40%) | 5 (50%) | 1 (10%) | ||
Rural/country | 2 (22%) | 5 (56%) | 2 (22%) | ||
GINA level of asthma control | |||||
Controlled | 3 (21%) | 8 (57%) | 3 (21%) | 0.39 | |
Partly controlled | 2 (18%) | 7 (64%) | 2 (18%) | ||
Uncontrolled | 5 (33%) | 4 (27%) | 6 (40%) | ||
Positive RAST testing | |||||
D. pteronyssinus | 4 (18%) | 11 (50%) | 7 (32%) | 0.65 | |
Grass mix | 4 (22%) | 6 (33%) | 8 (44%) | 0.07 | 2 vs 3 |
Cat dander | 2 (12%) | 10 (59%) | 5 (29%) | 0.41 | |
Dog dander | 2 (12%) | 7 (44%) | 7 (44%) | 0.16 | |
Birch | 0 (0%) | 5 (42%) | 7 (58%) | 0.005* | 1 vs 3; 2 vs 3; 2 vs 3 |
Mold | 1 (8%) | 5 (42%) | 6 (50%) | 0.1 | |
Treatment | |||||
ICS/LABA | 10 (24%) | 20 (49%) | 11 (27%) | – | |
SABA | 5 (18%) | 18 (64%) | 5 (18%) | 0.02* | 1 vs 2; 2 vs 3 |
LTRA | 2 (10%) | 12 (60%) | 6 (30%) | 0.11 | |
OCS | 1 (13%) | 3 (37%) | 4 (50%) | 0.34 | |
SABA/SAAC | 1 (33%) | 1 (33%) | 1 (33%) | 1 | |
LABA | 0 (0%) | 1 (100%) | 0 (0%) | 1 | |
Asthma status | |||||
% Predicted FEV1—mean (SD) | 72.3 ± 28.6 | 86.6 ± 18.6 | 80.2 ± 12.2 | 0.20 | |
ACQ total score—median (range) | 12.0 (2.0–14.0) | 8.0 (5.0–13.0) | 8.0 (4.0–13.0) | 0.77 | |
Exhaled nitric oxide—median (range) | 15.6 (7.1–46.7) | 20.8 (9.6–154.0) | 120.9 (5.7–236.0) | 0.82 |